FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2570671915> ?p ?o ?g. }

• W2570671915 endingPage "521" @default.
• W2570671915 startingPage "512" @default.
• W2570671915 abstract "Adenovirus infection in immunocompromised patients contributes to significant morbidity and mortality, especially after allogeneic hematopoietic cell transplantation (HCT). Brincidofovir (BCV, CMX001) is an orally bioavailable lipid conjugate of cidofovir that has in vitro activity against adenoviruses and other double-stranded DNA viruses. This randomized placebo-controlled phase II trial evaluated pre-emptive treatment with BCV for the prevention of adenovirus disease in pediatric and adult allogeneic HCT recipients with asymptomatic adenovirus viremia. Allogeneic HCT recipients with adenovirus viremia were randomized 1:1:1 to receive oral BCV 100 mg (2 mg/kg if <50 kg) twice weekly (BIW), BCV 200 mg (4 mg/kg if <50 kg) once weekly (QW), or placebo for 6 to 12 weeks, followed by 4 weeks of post-treatment follow-up. For randomization, subjects were stratified by screening absolute lymphocyte count (<300 cells/mm3 versus ≥300 cells/mm3). Assignment to BCV or placebo was double blinded; dose frequency was unblinded. The primary endpoint was the proportion of subjects experiencing treatment failure, defined as either progression to probable or definitive adenovirus disease or confirmed increasing adenovirus viremia (≥1 log10 copies/mL) during randomized therapy. Between June 2011 and December 2012, 48 subjects were randomized to the BCV BIW (n = 14), BCV QW (n = 16), or placebo (n = 18) groups. The proportion of subjects with treatment failure in the BCV BIW group was 21% (odds ratio, .53; 95% confidence interval [CI], .11 to 2.71; P = .45), 38% (odds ratio, 1.23; 95% CI, .30 to 5.05, P = .779) in the BCV QW group, and 33% in the placebo group. All-cause mortality was lower in the BCV BIW (14%) and BCV QW groups (31%) relative to the placebo group (39%), but these differences were not statistically significant. After 1 week of therapy, 8 of 12 subjects (67%) randomized to BCV BIW had undetectable adenovirus viremia (<100 copies/mL), compared with 4 of 14 subjects (29%) randomized to BCV QW and 5 of 15 subjects (33%) randomized to placebo. In a post hoc analysis of subjects with viremia ≥1000 copies/mL at baseline, 6 of 7 BCV BIW subjects (86%) achieved undetectable viremia compared with 2 of 8 placebo subjects (25%; P = .04). Early treatment discontinuation because of adverse events was more common in subjects treated with BCV than with placebo. Diarrhea was the most common event in all groups (57% BCV BIW, 38% BCV QW, 28% placebo), but it led to treatment discontinuation in only 1 subject receiving BCV QW. Events diagnosed as acute graft-versus-host disease, primarily of the gastrointestinal tract, were more frequent in the BCV BIW group (50%) than in the BCV QW (25%) and placebo (17%) groups. There was no evidence of myelotoxicity or nephrotoxicity in BCV-treated subjects. The results of this trial confirm the antiviral activity of BCV against adenoviruses. Further investigation is ongoing to define the optimal treatment strategy for HCT recipients with serious adenovirus infection and disease." @default.
• W2570671915 created "2017-01-13" @default.
• W2570671915 creator A5011497551 @default.
• W2570671915 creator A5012936889 @default.
• W2570671915 creator A5031592776 @default.
• W2570671915 creator A5044948809 @default.
• W2570671915 creator A5060384074 @default.
• W2570671915 creator A5065590894 @default.
• W2570671915 creator A5069222476 @default.
• W2570671915 creator A5070328573 @default.
• W2570671915 creator A5071388700 @default.
• W2570671915 date "2017-03-01" @default.
• W2570671915 modified "2023-10-14" @default.
• W2570671915 title "Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial" @default.
• W2570671915 cites W1546953993 @default.
• W2570671915 cites W1968444850 @default.
• W2570671915 cites W1976868395 @default.
• W2570671915 cites W1979440293 @default.
• W2570671915 cites W1980257364 @default.
• W2570671915 cites W1982015427 @default.
• W2570671915 cites W1982693802 @default.
• W2570671915 cites W1987522667 @default.
• W2570671915 cites W2000138652 @default.
• W2570671915 cites W2009665450 @default.
• W2570671915 cites W2021808977 @default.
• W2570671915 cites W2030143359 @default.
• W2570671915 cites W2034629930 @default.
• W2570671915 cites W2037302377 @default.
• W2570671915 cites W2041854719 @default.
• W2570671915 cites W2047819170 @default.
• W2570671915 cites W2049636812 @default.
• W2570671915 cites W2050599955 @default.
• W2570671915 cites W2059875959 @default.
• W2570671915 cites W2066019177 @default.
• W2570671915 cites W2089407167 @default.
• W2570671915 cites W2097640437 @default.
• W2570671915 cites W2116363211 @default.
• W2570671915 cites W2124967348 @default.
• W2570671915 cites W2130113751 @default.
• W2570671915 cites W2143909221 @default.
• W2570671915 cites W2159604048 @default.
• W2570671915 cites W2252447992 @default.
• W2570671915 cites W2312658128 @default.
• W2570671915 cites W2332112429 @default.
• W2570671915 cites W2553868906 @default.
• W2570671915 cites W2774396856 @default.
• W2570671915 doi "https://doi.org/10.1016/j.bbmt.2016.12.621" @default.
• W2570671915 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28063938" @default.
• W2570671915 hasPublicationYear "2017" @default.
• W2570671915 type Work @default.
• W2570671915 sameAs 2570671915 @default.
• W2570671915 citedByCount "113" @default.
• W2570671915 countsByYear W25706719152017 @default.
• W2570671915 countsByYear W25706719152018 @default.
• W2570671915 countsByYear W25706719152019 @default.
• W2570671915 countsByYear W25706719152020 @default.
• W2570671915 countsByYear W25706719152021 @default.
• W2570671915 countsByYear W25706719152022 @default.
• W2570671915 countsByYear W25706719152023 @default.
• W2570671915 crossrefType "journal-article" @default.
• W2570671915 hasAuthorship W2570671915A5011497551 @default.
• W2570671915 hasAuthorship W2570671915A5012936889 @default.
• W2570671915 hasAuthorship W2570671915A5031592776 @default.
• W2570671915 hasAuthorship W2570671915A5044948809 @default.
• W2570671915 hasAuthorship W2570671915A5060384074 @default.
• W2570671915 hasAuthorship W2570671915A5065590894 @default.
• W2570671915 hasAuthorship W2570671915A5069222476 @default.
• W2570671915 hasAuthorship W2570671915A5070328573 @default.
• W2570671915 hasAuthorship W2570671915A5071388700 @default.
• W2570671915 hasBestOaLocation W25706719151 @default.
• W2570671915 hasConcept C126322002 @default.
• W2570671915 hasConcept C142724271 @default.
• W2570671915 hasConcept C156957248 @default.
• W2570671915 hasConcept C168563851 @default.
• W2570671915 hasConcept C203014093 @default.
• W2570671915 hasConcept C204787440 @default.
• W2570671915 hasConcept C2522874641 @default.
• W2570671915 hasConcept C27081682 @default.
• W2570671915 hasConcept C2776185481 @default.
• W2570671915 hasConcept C2777408962 @default.
• W2570671915 hasConcept C2777910003 @default.
• W2570671915 hasConcept C2911091166 @default.
• W2570671915 hasConcept C71924100 @default.
• W2570671915 hasConcept C90924648 @default.
• W2570671915 hasConceptScore W2570671915C126322002 @default.
• W2570671915 hasConceptScore W2570671915C142724271 @default.
• W2570671915 hasConceptScore W2570671915C156957248 @default.
• W2570671915 hasConceptScore W2570671915C168563851 @default.
• W2570671915 hasConceptScore W2570671915C203014093 @default.
• W2570671915 hasConceptScore W2570671915C204787440 @default.
• W2570671915 hasConceptScore W2570671915C2522874641 @default.
• W2570671915 hasConceptScore W2570671915C27081682 @default.
• W2570671915 hasConceptScore W2570671915C2776185481 @default.
• W2570671915 hasConceptScore W2570671915C2777408962 @default.
• W2570671915 hasConceptScore W2570671915C2777910003 @default.
• W2570671915 hasConceptScore W2570671915C2911091166 @default.
• W2570671915 hasConceptScore W2570671915C71924100 @default.
• W2570671915 hasConceptScore W2570671915C90924648 @default.

• next